Protocol Ledger

NCT07509645 · Phase III · RECRUITING

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke

Interventional Phase III clinical trial protocol NCT07509645 sponsored by Capital Medical University in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-22 Enrollment: 348 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07509645
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)348 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07509645
Protocol FieldVerified Registry Value
NCT IdentifierNCT07509645
Consolidated Lead SponsorCapital Medical University
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment348 participants (ESTIMATED)
Registered Start Date2026-04-22
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI